BMY / Bristol Myers Squibb Enters Oversold Territory

Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer treatment p more_horizontal

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to more_horizontal

Bristol-Myers Squibb Co. BMY, +0.87% on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third quarter, up from $1.606 billi more_horizontal

Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Re more_horizontal

Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as t more_horizontal

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. more_horizontal

Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati more_horizontal

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy. more_horizontal